Citius Oncology (CTOR) Profit After Tax (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Profit After Tax data on file, last reported at -$26.6 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 243.99% year-over-year to -$26.6 million in Q1 2026; TTM through Mar 2026 was -$42.5 million, a 11.01% decrease from a year earlier, with the FY2025 full-year figure at -$24.8 million, down 17.08% from the prior year.
• Profit After Tax for Q1 2026 stood at -$26.6 million, down from -$5.5 million in the prior quarter.
• Over the last five years, Profit After Tax for CTOR reached as high as $1.4 million in Q3 2023 and fell as low as -$26.6 million in Q1 2026.
• Historically, Profit After Tax has averaged -$6.9 million across 4 years, with a median of -$5.5 million in 2025.
• Across the five-year window, Profit After Tax slumped 2426.12% in 2024 and jumped 62.54% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$4.7 million in 2023, then plunged by 40.86% to -$6.7 million in 2024, then grew by 16.9% to -$5.5 million in 2025, then tumbled by 380.83% to -$26.6 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$26.6 million in Q1 2026, -$5.5 million in Q4 2025, and -$5.0 million in Q3 2025.